Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics (Nasdaq: VERA) reported that on July 6, 2026, its Board Compensation Committee granted inducement equity awards to eight new employees under the 2024 Inducement Plan.

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) reported that on July 6, 2026, its Board Compensation Committee granted inducement equity awards to eight new employees under the 2024 Inducement Plan. The grants include non-qualified stock options for 32,100 Class A shares at an exercise price of $40.13 and RSUs for 16,050 Class A shares, all vesting over four years, in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus Jul 13 session 2 alerts

-1.19% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – VERA

$3.05B Mkt Cap at Peak Alert

On Jul 13, the first trading day after this news, VERA closed 1.19% below the previous close. Our momentum scanner recorded 2 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 13 session.

Key Figures

Stock options granted: 32,100 shares RSUs granted: 16,050 shares New employees: 8 employees +5 more

Stock options granted

32,100 shares

Non-qualified stock options under 2024 Inducement Plan for new employees

RSUs granted

16,050 shares

RSUs under 2024 Inducement Plan for new employees

New employees

8 employees

Recipients of inducement equity awards

Option exercise price

$40.13 per share

Exercise price equals closing price on July 6, 2026

Option vesting period

4 years

25% after one year, remainder monthly over 36 months

RSU vesting period

4 years

25% of shares vest on each anniversary of August 20

Initial option cliff

25% vesting

First anniversary of vesting commencement date

Monthly vesting duration

36 months

Remaining option shares vest monthly after first-year cliff

Historical Context

5 past events · Latest: Jul 09

5 events

1. Jul 09

   management transition

   24h Move

   +0.1%

   Announced CRO succession with retirement of William Turner and hire of Nancy Boman.

2. Jul 07

   FDA accelerated approval

   24h Move

   +7.0%

   FDA granted accelerated approval for TRUTAKNA in adults with primary IgA nephropathy.

3. Jun 05

   inducement equity grants

   24h Move

   -0.2%

   Granted stock options and RSUs to new employees under 2024 Inducement Plan.

4. Jun 02

   regulatory alignment

   24h Move

   -7.9%

   Announced FDA alignment on earlier ORIGIN Phase 3 analysis for atacicept in IgAN.

5. May 08

   inducement equity grants

   24h Move

   +1.2%

   Approved stock option and RSU inducement awards for new employees under plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan, +1 more

5 terms

non-qualified stock options financial

"inducement awards consisting of non-qualified stock options to purchase 32,100 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan)."

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

exercise price financial

"Each stock option granted on July 6, 2026 has an exercise price per share equal to $40.13"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on July 6, 2026 has an exercise price per share equal to $40.13, Vera Therapeutics’ closing trading price on July 6, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA^TM (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors 212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth Vera Therapeutics 415-854-8051
corporatecommunications@veratx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Vera Therapeutics (VERA) grant on July 6, 2026?

Vera Therapeutics granted stock options for 32,100 Class A shares and RSUs for 16,050 Class A shares. According to Vera Therapeutics, these awards were made to eight new employees under the 2024 Inducement Plan as employment inducements.

What is the exercise price of the new Vera Therapeutics (VERA) stock options granted in July 2026?

The exercise price is $40.13 per share for the options granted on July 6, 2026. According to Vera Therapeutics, this equals the company’s closing trading price of Class A common stock on that grant date.

How do Vera Therapeutics’ July 2026 inducement stock options vest for new employees?

The stock options vest over four years, with 25% vesting after one year and the rest monthly over 36 months. According to Vera Therapeutics, vesting requires continued service through each applicable vesting date.

What is the vesting schedule for the Vera Therapeutics (VERA) RSUs granted as inducement awards?

The RSUs vest over four years, with 25% of shares vesting on each anniversary of August 20. According to Vera Therapeutics, vesting is conditioned on the new employee’s continued service with the company.

Why were Vera Therapeutics (VERA) inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The awards were approved as inducements material to accepting employment, consistent with Nasdaq Listing Rule 5635(c)(4). According to Vera Therapeutics, they were granted under the 2024 Inducement Plan and related award agreements.